亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

美國Apexigen 
Apexigen是一家位于美國灣區(qū)的專注于治療性抗體的研發(fā)和市場化的生物制藥公司，廣泛與國內(nèi)外著名的生物制藥及生物技術(shù)公司如美國強聲、諾華制藥、先聲藥業(yè)，三生制藥等開展合作，擁有一流的抗體技術(shù)平臺及豐富的產(chǎn)品線，包括用于治療癌癥及炎癥的7個人源化兔單克隆抗體等。

Apexigen is a biopharmaceutcal company focused on discovering and developing best-in-class drugs from its proprietary monoclonal antibody technology platforms. Monoclonal antibodies specifically target cells or proteins that are essential components of diseases processes and activate the body’s immune system to remove or neutralize proteins and cells that cause or perpetuate disease.

Apexigen’s technology takes advantage of the extensive diversity in antibody specificity that is produced by the rabbit’s immune system. From this variety, very high affinity antibodies can be identified which have very exacting specificity and unique epitopes for disease targets. Such antibodies may have increased potency, efficacy and disease modifying ability.

Apexigen’s proprietary antibody technologies produce efficient capture of the rabbit’s innate antibody-making capability into stable, efficient hybridomas. Such stable hybridomas allow us to screen millions of individual antibodies and to select antibodies with optimal characteristics for drug development. The MLG humanization technology enables us to replace components of the rabbit monoclonal antibody with amino acid sequences that are commonly found in human antibodies. Humanization minimizes the possibility that patients will have immune or allergic reactions to treatment with the monoclonal antibody drug.

Apexigen was spun-out from Epitomics, Inc. in July of 2010. Apexigen has an exclusive, worldwide license to monoclonal antibody technologies developed by Epitomics for use in the development and commercialization of therapeutic antibodies. Epitomics will continue to utilize the technology to develop and commercialize rabbit antibodies for non-therapeutic uses.
Mission:

At Apexigen, our mission is to develop best-in-class antibody therapeutics for the treatment of human diseases with unmet medical needs.
Strategy:

Apexigen’s goal is to develop best-in-class antibody therapeutics. We will do that in two ways. We will collaborate with other pharmaceutical and biotechnology companies to utilize our technology platform to develop drugs against disease targets of interest to our partners while we at the same time discovering and developing our own pipeline of drugs.